Back to Results

ProKidney Corp (PROK)

ProKidney Corp. is a clinical-stage biotechnology company focused on developing cell therapies for chronic kidney disease in the United States. Its lead program, rilparencel, uses autologous selected renal cells and is being evaluated in a Phase III trial for advanced chronic kidney disease and type 2 diabetes. The company is also advancing cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008, both in Phase III studies. Additional pipeline programs include REGEN-002, REGEN-003, and REGEN-007 in Phase II, as well as REGEN-004 in Phase I. ProKidney was founded in 2015 and is headquartered in Winston-Salem, North Carolina. The company’s common stock is listed on the NASDAQ exchange under the symbol PROK.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-PROK
$1.57
-17.9% Downside
Fair
$6.25
227.2% Upside
Bargain
Weak
0.0%
November 16, 2026
693.4x
567.2 M
1.327 B
0.2%
76.8%
3.5
189.8%
Valuation • Fair Value

ProKidney Corp (NASDAQ-PROK) Fair Value by Valuation Model

Review the available estimates for ProKidney Corp (NASDAQ-PROK), including Comps Fair Value.

Primary Valuation Read

Fair Value

$1.57

Estimated downside of 17.9% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$1.57

Comparable-company valuation reference.

Analyst Price Target

$6.25

Analysts imply upside of 227.2%.

How to read these valuation models

Use the 4 available valuation references for ProKidney Corp (NASDAQ-PROK) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for ProKidney Corp (NASDAQ-PROK)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

818 K

Current operating scale indicator.

Revenue Forecast

522 K

Forward revenue estimate.

EBITDA

-170.4 M

Current operating profitability reference.

EBITDA Forecast

-178.3 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review ProKidney Corp (NASDAQ-PROK) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for ProKidney Corp (NASDAQ-PROK)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

2

Weak quality score that deserves closer review.

Altman Z-Score

3.5

Relatively strong balance-sheet zone.

FCF / Net Income

189.8%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for ProKidney Corp (NASDAQ-PROK). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for ProKidney Corp (NASDAQ-PROK)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 16, 2026

Days to Earnings

59

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for ProKidney Corp (NASDAQ-PROK), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

ProKidney Corp (NASDAQ-PROK) Stock Forecast & Technical Outlook

Review ProKidney Corp (NASDAQ-PROK) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for ProKidney Corp (NASDAQ-PROK) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for ProKidney Corp (NASDAQ-PROK) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for ProKidney Corp (NASDAQ-PROK) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for ProKidney Corp (NASDAQ-PROK) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for ProKidney Corp (NASDAQ-PROK) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for ProKidney Corp (NASDAQ-PROK)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Buy

Based on the available recommendation mix, ProKidney Corp (NASDAQ-PROK) has a Buy consensus, with 4 buy, 2 hold and 0 sell recommendations in the current data set.

Buy 4
Hold 2
Sell 0
FAQ • Fast Investor Answers

ProKidney Corp (NASDAQ-PROK) Stock FAQ

Data-supported answers about ProKidney Corp (NASDAQ-PROK), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$1.57
Estimated downside 17.9%
Valuation Rating
Overvalued
Estimated downside of 17.9%
Analyst Target
$6.25
Implied upside 227.2%
Financial Health
Weak
Current financial-health read

The current fair value estimate for ProKidney Corp (NASDAQ-PROK) is $1.57. This implies an estimated downside of 17.9% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 17.9% versus the current market price.

The available analyst price target for ProKidney Corp (NASDAQ-PROK) is $6.25. The analyst target implies estimated upside of 227.2%.

The current financial health read for ProKidney Corp (NASDAQ-PROK) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for ProKidney Corp (NASDAQ-PROK) is November 16, 2026.

The latest available data indicates no current dividend yield for ProKidney Corp (NASDAQ-PROK).

The current market capitalization listed for ProKidney Corp is 567.2 M.

The current enterprise value listed for ProKidney Corp is 1.327 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for ProKidney Corp is NASDAQ-PROK, and the stock is listed on NASDAQ.

ProKidney Corp (NASDAQ-PROK) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for ProKidney Corp is 0.2%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for ProKidney Corp is 76.8%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 466.4 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 208.5 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 186 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 128.8 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 78.353 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 62.595 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 61.522 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 53.245 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 40.928 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 39.9 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 32.055 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 31.841 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 28.748 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.206 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.4 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 24.131 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.214 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.751 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.546 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.864 B